Nu Skin Enterprises, Inc. (NUS) Stock Research Report

A deeply discounted, high-risk turnaround: Nu Skin is betting its future on AI-personalized beauty-tech devices that convert one-time sales into recurring wellness subscriptions.

Executive Summary

Nu Skin is in a difficult transition, attempting to reinvent itself from a traditional direct-selling/MLM company into an “intelligent beauty and wellness platform” built on social commerce and data-driven personalization. FY2025 revenue fell to ~$1.485B (-14% YoY), driven by weakness in key Asian markets (notably Mainland China and South Korea) and deterioration in field metrics (active customers down ~10%; Sales Leaders down ~19%), which threatens future sales capacity. Profitability rebounded sharply, but headline net income (~$160M) was heavily boosted by a one-time pre-tax gain (~$176M) from the Mavely divestiture; adjusted EPS (~$1.27) better reflects core improvement from cost actions under “Project Accelerate.” The business remains anchored by premium brands (Nu Skin, Pharmanex, ageLOC) and a device-led “razor-and-blade” model, with technology assets (Biophotonic Scanner history; Vera app; Prysm iO) positioned to drive recurring revenue if adoption and subscription conversion succeed.

Full Research Report

Nu Skin Enterprises, Inc. (NUS) Investment Analysis:

1. Executive Summary

Nu Skin Enterprises, Inc. (NUS) is currently navigating one of the most transformative and challenging periods in its four-decade history, attempting to pivot from a traditional direct-selling multi-level marketing (MLM) structure toward an "intelligent beauty and wellness platform" powered by social commerce and data-driven personalization.[1] Headquartered in Provo, Utah, the company has established itself as a global leader in premium personal care and wellness solutions, leveraging a vertically integrated manufacturing ecosystem and a expansive scientific foundation to differentiate its offerings in a highly fragmented global market.[2, 3] The company's primary mechanism for value creation has historically been its ability to combine professional-grade beauty devices with high-margin consumable products, creating a "razor-and-blade" ecosystem that facilitates recurring revenue and deep customer loyalty.[4, 5]

Nu Skin's revenue generation is organized into three primary pillars: Beauty (38.3% of 2025 revenue), Wellness (46.4%), and the Rhyz investment arm (15.3%), which includes manufacturing, technology, and strategic business incubations.[1] In 2025, the company recorded total revenue of $1.485 billion, representing a 14% year-over-year decline as the core Nu Skin business continued to face headwinds in key Asian markets, specifically Mainland China and South Korea.[1, 6] Despite top-line pressures, the company reported a significant rebound in profitability, with net income reaching $160.2 million compared to a substantial net loss in 2024; however, this figure was heavily influenced by a one-time pre-tax gain of approximately $176.2 million from the strategic sale of its Mavely business unit.[1, 7]

The company's core products are categorized under three flagship brands: Nu Skin (personal care), Pharmanex (nutritional supplements), and ageLOC (advanced anti-aging systems).[2] The ageLOC line, in particular, integrates the company's proprietary gene-expression science with IoT-connected devices such as the LumiSpa iO and the newly launched Prysm iO.[1, 8] These devices represent a significant portion of the company's competitive advantage, allowing it to hold the title of the world's number one brand for at-home beauty and wellness device systems for consecutive years according to Euromonitor International.[9, 10] Nu Skin's primary customer types are affluent, health-conscious consumers who prioritize clinically validated, premium anti-aging solutions. These customers are reached through a global network of nearly 130,000 paid affiliates and over 30,000 sales leaders who utilize social commerce tools and personalized consultations to drive engagement.[1, 7]

Key Metric (FY 2025) Result 2024 Comparison
Total Revenue $1,485.2 Million $1,732.1 Million (-14.3%) [1, 6]
Gross Margin 69.4% 68.2% (+120 bps) [1]
Operating Income $65.8 Million ($151.6 Million) (Recovery) [1]
Net Income $160.2 Million ($146.6 Million) (Incl. Mavely Gain) [1]
Diluted EPS $3.18 ($2.95) [1, 11]
Adjusted EPS $1.27 $0.84 (+51.2%) [7, 11]
Active Customers 748,796 831,993 (-10.0%) [1, 7]
Sales Leaders 30,045 37,090 (-19.0%) [1, 7]

The most important end markets for Nu Skin are highly international, with 74% of revenue generated outside the United States.[1] Key regions include the Americas (26% of revenue), Southeast Asia/Pacific, Mainland China, Japan, and South Korea.[1] Customers choose Nu Skin over alternatives—ranging from prestige retail brands like Estée Lauder to other direct sellers like Amway—primarily because of the company’s "clinical validation" and the tangible feedback provided by its technology ecosystem. For instance, the Biophotonic Scanner allows users to non-invasively measure their antioxidant levels, providing immediate "proof of efficacy" for its nutritional supplements that traditional retail products cannot match.[5, 8, 10]

TRANSITIONING TOWARD GROWTH

2. Business Drivers & Strategic Overview

Revenue Drivers and Product Analysis

Nu Skin’s financial engine is increasingly shifting from traditional product sales toward a technology-integrated "intelligent wellness" model. The company’s revenue is driven by a unique synergy between hardware (beauty and wellness devices) and consumables (topical treatments and nutritional supplements).[4, 5] An investor must understand that the physical product being sold is often just the entry point into a multi-year data relationship with the consumer.

The Wellness segment (46.4% of revenue) is led by the Pharmanex brand, which utilizes pharmaceutical-grade processing to ensure the efficacy of its nutritional supplements.[1, 3] The recent launch of the Prysm iO platform is the centerpiece of the company's 2026 growth strategy.[11, 12] This palm-sized device uses biophotonic technology to scan a user’s fingertip and assess their carotenoid levels, providing an "antioxidant score".[1, 8] This data point is then used by the company’s AI-powered Vera app to recommend specific LifePak or other supplements, effectively automating the upselling process for brand affiliates.[5, 8, 13] Management expects to place 100,000 Prysm iO units by the end of 2026, creating a $30 million direct hardware revenue opportunity and, more importantly, a significant tailwind for high-margin, recurring supplement subscriptions.[12, 14]

The Beauty segment (38.3% of revenue) focuses on anti-aging skincare, anchored by the ageLOC franchise.[1, 2] The ageLOC LumiSpa iO, a connected facial cleansing device, serves as a primary acquisition tool. It provides a "connected" experience where users can track their skin goals through an app, which in turn monitors consumable usage and triggers reordering.[5, 13] The 2025 refresh of the ageLOC Tru Face line, emphasizing "clean" ingredients and sustainable packaging, reflects the company’s alignment with broader consumer trends toward "healthspan" and environmental consciousness.[9, 15, 16]

The Rhyz segment (15% of revenue) represents a critical strategic advantage that is often overlooked. It includes Wasatch Product Development, a manufacturing entity that allows Nu Skin to internalize R&D and production for a majority of its products.[2, 17] This vertical integration allows for faster innovation cycles and better margin control during periods of supply chain volatility.[1, 5] The Rhyz segment also acts as a strategic investment arm; the $250 million sale of Mavely in early 2025 demonstrated the company's ability to incubate technology platforms and monetize them to strengthen its balance sheet and fund core growth initiatives like the India expansion.[1, 12]

Moat and Competitive Advantages

Nu Skin’s "moat" is multi-dimensional, combining technical barriers to entry with high psychological and financial switching costs for its customer base.

  1. Device-plus-Consumable Ecosystem (High Switching Costs): Once a consumer invests approximately $300 in a LumiSpa iO or a Prysm iO device, the barrier to switching to a competitor's cleanser or supplement becomes high.[12, 14] The devices are designed to function optimally with proprietary Nu Skin formulations, creating a locked ecosystem that drives lifetime value (LTV). The data integrated into the Vera app—tracking months of skin or nutritional progress—creates a "data moat" where the cost of leaving is the loss of personalized health history.[5, 8, 13]
  2. Intellectual Property and Scientific Validation: Nu Skin maintains an extensive patent portfolio, including over 28 patents specifically related to its anti-aging gene-expression science.[18] Its research is supported by a global team of internal scientists and collaborations with top-tier research institutions, providing a level of "clinical credibility" that mass-market retail brands struggle to replicate.[3, 4, 19]
  3. The Biophotonic Scanner Network (Network Effects/Scale): With over 20 million scans across 50 countries, Nu Skin owns one of the world's largest longitudinal databases of antioxidant levels.[8] This scale allows the company to use machine learning to refine its personalized wellness recommendations, creating a self-reinforcing loop where more users lead to better data, which leads to better products and higher retention.[2, 8]
  4. Distribution Advantage (The Affiliate Field): While the MLM model faces regulatory scrutiny, the "human touch" of 130,000 affiliates remains a powerful distribution tool for complex, premium products that require education.[1] This network acts as a decentralized marketing force that can pivot to social commerce channels (TikTok, Instagram) more rapidly than centralized corporate marketing departments.[1, 8]

TAM and Market Opportunity

Nu Skin is positioned at the intersection of several high-growth global markets, benefiting from the blurring lines between beauty and health.

Market Segment Projected Value Growth Forecast (CAGR)
Global Personal Care $3.3 Trillion (by 2032) 8.6% [12]
Global Beauty Tech $173 Billion (by 2030) 17.9% [20]
At-Home Beauty Devices $166 Billion (by 2030) 12.1% [21]
Nutritional Supplements $485 Billion (2024 Base) 6.4% [8]
Consumer Health $338 Billion (2025 Base) 4.0% [15]

The most significant opportunity lies in "Beauty from Within" (nutricosmetics), where the Asia-Pacific market is leading the trend.[15, 22] Nu Skin's biophotonic technology and Prysm iO platform are uniquely positioned to capture this "beauty-health" convergence.[10, 15] Furthermore, the company’s planned entry into India in late 2026 targets one of the fastest-growing middle-class populations in the world, providing a massive expansion of its addressable market beyond its current 50-market footprint.[11, 12]

Competitive Landscape

The competitive environment for Nu Skin is divided into three tiers: direct selling peers, prestige beauty conglomerates, and at-home device specialists.

  1. Direct Selling Peers: Amway ($7.4B revenue), Herbalife ($5.0B revenue), and USANA ($925M revenue) are the primary rivals for field talent and consumer mindshare in the wellness space.[23, 24] In 2025, Nu Skin "lost ground" relative to USANA and Herbalife, as its revenue declined by 14% while USANA grew by 8.2% and Herbalife stabilized.[23] Amway remains the dominant player in nutrition (Nutrilite), but Nu Skin differentiates itself by being the only major player with a dominant "device-first" strategy.[4, 24, 25]
  2. Prestige Beauty Conglomerates: L'Oréal and Estée Lauder are increasingly moving into Nu Skin's territory by launching AI-driven diagnostics and "beauty as a service" models.[20, 21] L'Oréal's introduction of infrared light hair dryers and GenAI-powered skin diagnostics represents a direct challenge to Nu Skin’s technology leadership.[20]
  3. At-Home Device Specialists: Brands like FOREO and Tria Beauty compete on high-design aesthetics and specific clinical use cases (e.g., laser hair removal).[21] Nu Skin generally "holds ground" here due to its community-based selling model, which provides a higher level of user instruction and compliance than pure-play retail devices.[4, 21]

STRATEGICALLY REPOSITIONING AS BEAUTY-TECH

3. Financial Performance & Valuation

2025 Historical Performance Review

Fiscal year 2025 was a "tale of two halves" for Nu Skin, where structural revenue contraction was offset by aggressive margin management and strategic asset monetization.

  • Top-Line Contraction: Total revenue of $1.485 billion was down 14.3% YoY.[1, 7] This was driven by a continued decline in the active customer base (-10%) and, more critically, a 19% drop in Sales Leaders.[1, 7] The loss of high-level sales leaders is a leading indicator of future revenue pressure, as it signals a weakening of the recruitment and motivation engine of the affiliate field.[7, 23]
  • Geographic Performance: Revenue declines were broad-based across all regions except Latin America, which saw strong growth.[6, 26] Mainland China revenue fell 16.9% (currency-neutral), reflecting the difficult regulatory and economic climate in that region.[6] South Korea, another key market, saw a 20.5% decline.[6]
  • Profitability and the Mavely Impact: Reported diluted EPS of $3.18 was a massive increase from the $(2.95) loss in 2024.[11] However, this includes a $176.2 million gain from the sale of Mavely.[1] Adjusted EPS, which excludes restructuring and one-time items, was $1.27—a 51% increase over 2024’s adjusted figure.[7, 11] This improvement in "core" profitability was achieved through "Project Accelerate," which optimized the product portfolio and reduced global overhead, leading to an operating margin of 6.3% (or 7.7% adjusted).[1, 13, 14]

Financial Drivers and Valuation Analysis

Nu Skin’s valuation is currently depressed, trading at levels that suggest the market is pricing in a permanent impairment of the direct-selling model.

Valuation Multiple Current Value (Apr 2026) Market/Sector Average
Price / Earnings (LTM) 2.3x [27, 28] 12.0x - 19.5x [28]
Price / Earnings (Forward) 7.4x [29] -
Price / Sales (TTM) 0.24x [28, 30] 0.9x - 2.3x [28]
Price / Book Value 0.44x [28, 31] 1.5x - 2.7x [28]
EV / EBITDA (TTM) 2.96x [29] -
Dividend Yield 3.3% [32] -

The most important financial drivers for valuation include:

  1. Revenue Stabilization (5-Year Sales Growth): The market is currently valuing NUS as a declining asset. A shift toward even flat revenue growth ($1.4B - $1.5B range) would likely trigger a re-rating of the multiple.[11, 14]
  2. Field Health: The number of Sales Leaders and Paid Affiliates are the primary leading indicators. Valuation will remain under pressure until these metrics stabilize, as they represent the "installed capacity" of the revenue engine.[7, 23]
  3. Subscription Conversion: As the company shifts toward its "Intelligent Wellness Platform," the ratio of one-time hardware sales to recurring subscription revenue becomes a key margin driver. Management anticipates high-margin recurring streams from Prysm iO as individuals receive personalized recommendations through the app.[12, 13]
  4. Capital Structure and Liquidity: Nu Skin ended 2025 with $240 million in cash and reduced debt to $224 million, representing a net cash position.[13] The recent $175 million term loan and $75 million revolver additions in March 2026 provide further liquidity to fund the India market opening and potential strategic M&A in the Rhyz ecosystem.[2, 13]

UNDERVALUED RELATIVE TO ASSETS

4. Risk Assessment & Macroeconomic Considerations

Regulatory and Legal Risks

Nu Skin operates in a highly scrutinized industry where regulatory changes can happen abruptly and have catastrophic impacts on the business model.

  • FTC Rulemaking on Earnings Claims: In January 2025, the U.S. Federal Trade Commission (FTC) proposed the "Earnings Claim Rule Regarding Multi-Level Marketing".[33, 34] This rule would prohibit deceptive income claims and, critically, require companies to provide written substantiation for any earnings statements made to prospects.[34, 35] The expansion of these rules to allow the FTC to seek civil penalties post-violation adds a layer of financial risk that could severely limit the company's ability to recruit new affiliates in its domestic market.[34, 36]
  • Mainland China Scrutiny: China’s regulatory environment for direct selling is notoriously complex and "evolving".[1, 37] Any government crackdown on the MLM model, similar to the 2019 "Hundred Day Action," could lead to the immediate suspension of meeting licenses or hefty fines, which would be devastating given China’s historically significant contribution to revenue (14% currently, but previously over 25%).[1, 4, 14]

Execution and Competitive Risks

  • Transformation Friction: The shift from a traditional MLM model to a "social-first" social commerce platform involves significant "inherent switching costs".[13, 38] Traditional sales leaders may find it difficult to adapt to social-first practices, leading to higher-than-expected attrition in the field organization as the company "realigns business practices".[38]
  • The Gig Economy Threat: Nu Skin is no longer just competing with Amway; it is competing with Uber, DoorDash, and TikTok for the "share of time" of entrepreneurial individuals.[1] The transparency and immediate payout of gig economy platforms are major competitive threats to the longer-term commission structure of Nu Skin.[1]
  • Geographic Concentration: While Nu Skin operates in 50 markets, its reliance on a few key Asian hubs (China, South Korea, Japan) makes it vulnerable to regional economic downturns or shifts in local consumer sentiment.[5, 6]

Macroeconomic Sensitivities

  • Foreign Currency Volatility: Since 74% of revenue is international, Nu Skin is highly sensitive to the strength of the U.S. Dollar.[1] In 2025, the company faced a $13.4 million FX headwind, and it expects a further 1% headwind in 2026.[1, 11]
  • Inflation and Consumer Spending: As a premium brand, Nu Skin’s products are discretionary. High global inflation can squeeze the "wallet share" of its middle-class customers, particularly in emerging markets where price sensitivity is higher.[1, 14]

Risk Hierarchy: What Could Go Wrong

  1. What Could Go Wrong: A final FTC rule that effectively bans "lifestyle" marketing, combined with a total loss of direct-selling licenses in China.
  2. Early Warning Signs: Continued double-digit declines in Sales Leader counts for more than two consecutive quarters in 2026, or a failure to reach the 100,000-unit goal for Prysm iO.[7, 14]
  3. Maximum Thesis Damage: A situation where "Project Accelerate" cost-cutting measures reach their limit, but revenue continues to fall, leading to negative operating leverage and the suspension of the dividend.[1, 13]

SIGNIFICANT REGULATORY OVERHANG

5. 5-Year Scenario Analysis

Base Case: Stabilization and Pivot Success (50% Probability)

In the base case, Nu Skin successfully navigates the "transition year" of 2026. The launch of Prysm iO proves successful, with units reaching 100,000 in FY26 and growing at a 15% CAGR thereafter. The India market contributes $50M+ in revenue by Year 3.

  • Key Fundamentals: Revenue stabilization in 2026 followed by a 3% CAGR. Operating margins stabilize at 8% as G&A is leveraged.
  • Valuation Assumptions: Revenue reaches $1.65B by Year 5. Adjusted net income of $115M. Share count remains flat at 48M (assuming repurchases offset dilution).
  • Exit Multiple: 10x P/E (reflecting a stabilized but slow-growth consumer staple).
  • Implied Price: $\frac{\$115M}{48M} \times 10 = \$23.96$.
  • Trajectory:
    • Year 1 (2026): $7.41 (Guidance Year)
    • Year 3 (2028): $14.50 (Growth in India/Subscriptions)
    • Year 5 (2030): $23.96 (Stabilized Platform)

High Case: The Intelligent Wellness Revolution (15% Probability)

The High Case assumes the "Beauty-Tech" re-rating occurs as subscription revenue becomes a dominant part of the mix. India becomes a top-3 market within five years.

  • Key Fundamentals: Revenue CAGR of 6% over five years. Operating margins expand to 12% as the "Rhyz" ecosystem produces another $250M+ exit.
  • Valuation Assumptions: Revenue reaches $1.95B by Year 5. Net income of $180M. Share count reduced to 42M via aggressive $142M repurchase authorization.[11]
  • Exit Multiple: 15x P/E (reflecting a technology-driven high-margin wellness business).
  • Implied Price: $\frac{\$180M}{42M} \times 15 = \$64.28$.
  • Trajectory:
    • Year 1: $12.00 (Sentiment Shift)
    • Year 3: $35.00 (Rapid India Scale)
    • Year 5: $64.28 (Tech-Multiple Re-rating)

Low Case: Regulatory/Field Collapse (35% Probability)

The Low Case assumes the FTC rule cripples the U.S. field, and the China market never recovers due to regulatory changes. India launch is delayed and over-budget.

  • Key Fundamentals: Revenue continues to decline at a 5% annual rate. Operating margins compressed to 3% due to legal costs and lack of scale.
  • Valuation Assumptions: Revenue falls to $1.15B by Year 5. Net income of $25M. No repurchases; 48M shares.
  • Exit Multiple: 5x P/E (reflecting a "melting ice cube" terminal decline).
  • Implied Price: $\frac{\$25M}{48M} \times 5 = \$2.60$.
  • Trajectory:
    • Year 1: $5.50 (Guidance Miss)
    • Year 3: $4.00 (Continued Attrition)
    • Year 5: $2.60 (Value Trap Realized)

Scenario Table Summary

Scenario Year 5 Revenue EPS Assumption Valuation Multiple Implied Price 5-Year Return Probability
High Case $1.95 Billion $4.29 15.0x P/E $64.28 ~767% 15%
Base Case $1.65 Billion $2.40 10.0x P/E $24.00 ~224% 50%
Low Case $1.15 Billion $0.52 5.0x P/E $2.60 -65% 35%

Probability-Weighted Target (5-Year): $22.55

HIGHLY ASYMMETRIC UPSIDE

6. Qualitative Scorecard

Metric Score (1-10) Narrative
Management Alignment 7 CEO Ryan Napierski has a 9-year tenure and owns 2.08% of shares ($7.4M).[19] Performance-based RSUs align pay with meeting EPS targets.[37]
Revenue Quality 4 Currently poor due to reliance on a shrinking MLM field, but high gross margins (70%) and a shift toward subscription models provide a path to improvement.[1, 14]
Market Position 6 Dominant #1 position in devices [9, 10], but losing ground in total wellness/skincare share to Sephora/DTC and retail-backed beauty tech.[20, 23]
Growth Outlook 5 Near-term pressure is significant (2026 guidance is cautious), but long-term catalysts in India and AI-personalization are credible.[11, 12]
Financial Health 8 Strong. Net cash position, high current ratio (2.06), and a solid $240M cash buffer despite revenue declines.[13, 27, 39]
Business Viability 4 Choke points are heavy. Regulatory shifts in the US/China or a platform-wide ban on MLM content would break the business.[1, 34]
Capital Allocation 7 Disciplined. 34 years of dividend increases (though yield is high, safety is a concern), and successful capital recycling via the Mavely exit.[1, 12]
Analyst Sentiment 2 Very poor. Consensus "Reduce" rating with 1 Sell and 1 Hold in the last 90 days. Skepticism on the "intelligent wellness" pivot is high.[30, 40, 41]
Profitability 6 Strong gross margins (77.6% in core business) are the bedrock of the thesis, but operating margins need to recover from the low single digits.[1, 13, 14]
Track Record 6 Decades of global expansion and innovation, but the last 5 years have been a period of significant shareholder value destruction (-86%).[42]

OVERALL BLENDED SCORE: 5.6 / 10

DEEP VALUE OPPORTUNITY

7. Conclusion & Investment Thesis

Nu Skin Enterprises, Inc. represents a high-conviction "deep value" opportunity that is currently being valued as a "melting ice cube" by the broader market.[28, 40] The company’s core business model is undeniably under pressure from a confluence of regulatory scrutiny in the U.S. and China, the demographic shift toward the gig economy, and the rise of retail-backed beauty technology.[1, 34] However, the current valuation at ~2.3x LTM earnings and 0.44x book value prices in a near-total collapse of the enterprise, which the company’s strong balance sheet ($240M cash, net cash position) and 77% core gross margins do not support.[13, 28]

The investment thesis centers on the success of the "Intelligent Wellness" pivot. If the Prysm iO platform can successfully bridge the gap between beauty and data-driven health, Nu Skin can transition its revenue from high-churn product sales to high-margin, sticky subscriptions.[8, 13] The 2026 entry into India provides a substantial geographic "call option" that could offset the structural decline in mature markets.[11, 12] While execution and regulatory risks are high, the asymmetric upside in the Base and High cases suggests that the market may be overly pessimistic about the durability of the Nu Skin ecosystem.

HIGH-RISK TURNAROUND PIVOT

8. Technical Analysis, Price Action & Short-Term Outlook

Nu Skin (NUS) is currently in a primary downtrend, trading at $7.41, which is significantly below its 200-day moving average of $9.86 and its 50-day average of $8.74.[43, 44] The stock recently reached a 52-week low of $5.32, and while there has been a minor "pivot bottom" buy signal in mid-March showing a 4.2% rise, the long-term momentum remains bearish.[43, 45] Relative Strength Index (RSI) at 36.4 indicates the stock is approaching oversold territory, but the absence of a confirmed "Golden Cross" suggests a lack of buying support.[43, 45] Short-term outlook is neutral-to-bearish as the market awaits the May 7, 2026 earnings release to gauge 2026 guidance execution.[43, 46]

BEARISH MOMENTUM LINGERS

  1. NU SKIN ENTERPRISES, INC. SEC 10-K Report - TradingView, https://www.tradingview.com/news/tradingview:73a7e0bd9e7a9:0-nu-skin-enterprises-inc-sec-10-k-report/
  2. NUS Stock Price, News & Analysis | Nu Skin Enter, https://www.stocktitan.net/overview/NUS/
  3. Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results, https://www.nuskin.com/content/corpcom/en_US/newsroom/press_releases1/2026/nu-skin-enterprises-to-announce-fourth-quarter-and-full-year-202.html
  4. What is Competitive Landscape of Nu Skin Enterprises Company? - Porter's Five Forces, https://portersfiveforce.com/blogs/competitors/nuskin
  5. Nu Skin Enterprises, Inc. (NUS): history, ownership, mission, how it works & makes money, https://www.dcfmodeling.com/blogs/history/nus-history-mission-ownership
  6. Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance, https://www.nuskin.com/content/corpcom/en_US/newsroom/press_releases1/2026/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025.html
  7. Earnings rebound at Nu Skin (NYSE: NUS) as 2025 EPS hits $3.18 - Stock Titan, https://www.stocktitan.net/sec-filings/NUS/8-k-nu-skin-enterprises-inc-reports-material-event-6b59b89b02df.html
  8. Nu Skin Enterprises, Inc. (NUS) Stock Price, Market Cap, Segmented Revenue & Earnings, https://www.datainsightsmarket.com/companies/NUS
  9. 2025 - Nu Skin, https://www.nuskin.com/content/corpcom/en_US/newsroom/press_releases1/2025.html
  10. Nu Skin Ranked the World's #1 Company for Beauty and Wellness Device Systems for Second Consecutive Year - Business Wire, https://www.businesswire.com/news/home/20250930626414/en/Nu-Skin-Ranked-the-Worlds-1-Company-for-Beauty-and-Wellness-Device-Systems-for-Second-Consecutive-Year
  11. Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance, https://www.nasdaq.com/press-release/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025-results-within-guidance
  12. Company Updates - Strategic Investor Engagement | Stonegate, https://stonegateinc.com/wp-content/uploads/2026/02/NUS-Report-25Q4.pdf
  13. Nu Skin (NUS) Q4 2025 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/02/12/nu-skin-nus-q4-2025-earnings-call-transcript/
  14. Nu Skin Q4 2025 slides: Revenue declines across regions as margins improve, https://www.investing.com/news/company-news/nu-skin-q4-2025-slides-revenue-declines-across-regions-as-margins-improve-93CH-4504212
  15. Beauty and healthspan reshape the USD338 billion consumer health market, https://www.euromonitor.com/newsroom/press-releases/february-2026/beauty-and-healthspan-reshape-the-usd338-billion-consumer-health-market
  16. Beauty Consumer Trends: Key Insights from the Voice of the Consumer Survey, https://www.euromonitor.com/article/beauty-consumer-trends-key-insights-from-the-voice-of-the-consumer-survey
  17. Nu Skin Enterprises, Inc. (NUS) Q4 2025 Earnings Call Transcript | Seeking Alpha, https://seekingalpha.com/article/4869879-nu-skin-enterprises-inc-nus-q4-2025-earnings-call-transcript
  18. Anti-Aging Patents - Nu Skin, https://www.nuskin.com/en_US/topnav-skin-and-beauty/science/patents.html
  19. Nu Skin Enterprises, Inc. (NUS) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/household/nyse-nus/nu-skin-enterprises/management
  20. Beauty Tech Market Size And Share | Industry Report, 2030 - Grand View Research, https://www.grandviewresearch.com/industry-analysis/beauty-tech-market-report
  21. Beauty Devices Market Size ($165.7 Billion) 2030, https://www.strategicmarketresearch.com/market-report/beauty-devices-market
  22. Health & Beauty: Market Research & Trends - Euromonitor.com, https://www.euromonitor.com/industry/health-beauty
  23. Public Product Companies—2025 Year-End Earnings Review - Direct Selling News, https://www.directsellingnews.com/2026/03/16/public-product-companies-2025-year-end-earnings-review/
  24. What is Competitive Landscape of Amway Corporation Company? - Matrix BCG, https://matrixbcg.com/blogs/competitors/amway
  25. Top 10 Direct Selling Companies in North America | 2026 - Expert Market Research, https://www.expertmarketresearch.com/blogs/top-direct-selling-companies-in-north-america
  26. What is Competitive Landscape of Nu Skin Enterprises Company? - PESTEL Analysis, https://pestel-analysis.com/blogs/competitors/nuskin
  27. Buy Nu Skin Enterprises Stock – NUS Stock Quote Today & Investment Insights - Public.com, https://public.com/stocks/nus
  28. Nu Skin Stock Price Today | NYSE: NUS Live - Investing.com, https://www.investing.com/equities/nu-skin-enterprises-inc
  29. Nu Skin Enterprises, Inc. (NUS) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/NUS
  30. Nu Skin Enterprises (NUS) Stock Price, News & Analysis - MarketBeat, https://www.marketbeat.com/stocks/NYSE/NUS/
  31. Nu Skin Enterprises (NYSE:NUS) - Stock Analysis - Simply Wall St, https://simplywall.st/stocks/us/household/nyse-nus/nu-skin-enterprises
  32. Nu Skin Enterprises, Inc. stock - Saxo Bank, https://www.home.saxo/markets/stocks/nus-xnys
  33. FTC Rule Overhaul: How New Regulations Will Shake Up MLM in 2025 - FlawlessMLM, https://flawlessmlm.com/en/blog/ftc-mlm-rules-2025
  34. FTC Proposes Rule Changes and New Rule to Deter Deceptive Earnings Claims by Multilevel Marketers and Money-Making Opportunity Sellers, https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-proposes-rule-changes-new-rule-deter-deceptive-earnings-claims-multilevel-marketers-money-making
  35. FTC Puts Pedal to the Metal to Release Proposed Rule on MLM Earnings Claims, Changes to Business Opportunity Rule—but Republican Commissioners Pump the Brakes in Potential Foreshadowing - Kelley Drye & Warren LLP, https://www.kelleydrye.com/viewpoints/blogs/ad-law-access/ftc-puts-pedal-to-the-metal-to-release-proposed-rule-on-mlm-earnings-claims-changes-to-business-opportunity-rule-but-republican-commissioners-pump-the-brakes-in-potential-foreshadowing
  36. Proposed Rule Changes and an Executive Order: What It Means for Direct Selling Companies - BBB National Programs, https://bbbprograms.org/media/insights/blog/proposed-rule-eo
  37. NUS SEC Filings - Nu Skin Enter 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/NUS/page-3.html
  38. Nu Skin Enterprises Q4 2025 Earnings Report - MarketBeat, https://www.marketbeat.com/earnings/reports/2026-2-13-nu-skin-enterprises-inc-stock/
  39. nu skin enterprises inc - stockinsights.ai, https://www.stockinsights.ai/us/NUS/10-Q/fy25-q3-10ba
  40. Nu Skin Enterprises (NUS) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NYSE/NUS/forecast/
  41. Nu Skin Enterprises, Inc. $NUS Shares Purchased by American Century Companies Inc., https://www.marketbeat.com/instant-alerts/filing-nu-skin-enterprises-inc-nus-shares-purchased-by-american-century-companies-inc-2026-03-11/
  42. Nu Skin Enterprises (NUS) Stock Chart and Price History 2026 - MarketBeat, https://www.marketbeat.com/stocks/NYSE/NUS/chart/
  43. Nu Skin Enterprises (NUS) Statistics & Valuation - Stock Analysis, https://stockanalysis.com/stocks/nus/statistics/
  44. JPMorgan Chase & Co. Lowers Holdings in Nu Skin Enterprises, Inc. $NUS - MarketBeat, https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-lowers-holdings-in-nu-skin-enterprises-inc-nus-2026-04-01/
  45. Nu Skin Enterprises Stock Price Forecast. Should You Buy NUS? - StockInvest.us, https://stockinvest.us/stock/NUS
  46. NUS Forecast, Price Target & Analyst Ratings | NU SKIN ENTERPRISES INC - ChartMill, https://www.chartmill.com/stock/quote/NUS/analyst-ratings

View Nu Skin Enterprises, Inc. (NUS) stock page

Loading the interactive version of this report…